Mondelez Sends Observers to Cocoa Farm in Ghana and 2 More Heavily Traded Stocks to Follow

Mondelez International Inc. (NASDAQ:MDLZ): Current price $30.93

The biggest maker of chocolate, candy, biscuits, gum, coffee, and powdered beverages on the planet is sending nine worldwide employees from to learn and serve in cocoa-farming communities in Ghana. The pilot Joy Ambassadors program unites employees from seven countries: Brazil, China, the United States, the United Kingdom, Russia, Sweden, and Switzerland to learn directly from cocoa communities of their successes and challenges while sharing employees’ diverse business skills.


Vodafone Group Plc (NASDAQ:VOD): Current price $35.43

The Kabel Deutschland Holding shareholder Elliott Management Corp. is stalling while Vodafone tries to persuade investors to cash out so that it may finalize its takeover of the German cable company. At a Friday shareholder meeting in München, it was revealed that Elliott has not reduced its 11-percent holding since September, at which time investors were requested to tender their Kabel Deutschland shares to Vodafone. A knowledgeable sources opines that the hedge fund might be betting it can force a higher price from Vodafone using that strategy. In Germany, investors may decline to sell during a takeover attempt and ask for a higher price, leaving the matter for a court decision on the stock’s value.


Amarin Corp. (NASDAQ:AMRN): Current price $5.09

FDA staff say that expanding the use of Amarin’s fish oil drug, cleared in 2012 to treat people with “very high” triglycerides, may depend on the outcome of a study on heart risks. The agency made the determination regarding the prescription-grade omega-3 fatty acid, Vascepa, in a report posted Friday on its website. A panel of FDA advisers will meet October 16 to discuss expanded approval for the drug to persons with only high triglycerides, a fat in the blood, who also are using a cholesterol-lowering statin therapy. Amarin is evaluating Vascepa’s ability to lower cardiovascular events.


Don’t Miss: IRS to Congress: Obamacare Glitches Not Our Fault.